AzTrials
AzTrials

Esophagus CancerPROFUGONCT05390684

Predictive Model to Early Diagnosis of Anastomotic Leak After Esophagectomy and Gastrectomy.

An observational study of Esophagus Cancer and Gastric Cancer, run by Hospital Universitario La Fe at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The PROFUGO study (PRedictive Model for the early diagnosis of anastomotic leak after esophagectomy and gastrectomy) is proposed as a prospective and multicenter study at spanish national level that aims to develop, with the help of artificial intelligence methods, a tool and predictive model that allows identifying… Read more about this study

Who is it for?
Ages 18 to 85 years
What is being tested?
audit of complications, prospective data collection
How many people
800 participants
Where
1 siteSpain
Study dates
1 May 2022to 31 Dec 2023
How long will I take part?
90 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients diagnosed with neoplasia of the esophagus or stomach with an indication for oncological surgery with curative intention in any of the centers participating in the study.

Who may be able to join

  • Patients with a surgical indication and curative intent due to esophagogastric neoplasia who do not meet exclusion criteria and recruited by hospitals nationwide that decide to participate in the study will be included.

Who cannot join

  • Patients under 18 or over 85 years
  • Patients with chronic infections
  • Patients with synchronous tumors in other locations
  • Patients with autoimmune disease
  • Patients who die in the operating room
  • Patients who do not sign the informed consent to participate in the study
Show all 10Show fewer
  • Patients in clinical stage IVB
  • Surgical resection R2 (there are macroscopic remains of the tumor in the surgical field after performing the resection of the surgical piece)
  • Combined intraoperative resection of other organs
  • Surgeries without anastomosis

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Marcos Bruna

    Valencia, 46003

Other trials in Spain

About this study

Official title: Predictive Model to Early Diagnosis of Anastomotic Leak After Esophagectomy and Gastrectomy. PROFUGO Study.

The PROFUGO study (PRedictive Model for the early diagnosis of anastomotic leak after esophagectomy and gastrectomy) is proposed as a prospective and multicenter study at spanish national level that aims to develop, with the help of artificial intelligence methods, a tool and predictive model that allows identifying cases with a high risk of anastomotic leak (AF) and/or major complications through the analysis of different clinical and analytical variables collected during the perioperative period of patients undergoing esophagectomy or gastrectomy.

2.-HYPOTHESIS

Read more

Early identification of patients at high risk of developing AF and/or major complications after esophagogastric surgery can be carried out through the perioperative study of objective clinical variables and analytical markers.

3.-OBJECTIVE

The main objective of the study is to design a predictive model based on clinical and analytical variables that allow the identification of patients with a high risk of anastomotic leak (main variable) and/or major complication during the postoperative period of esophagogastric surgery.

4.-MATERIAL AND METHODS

  • DESIGN: Prospective and multicenter study of 1 year duration.
  • STUDY POPULATION: Patients diagnosed with neoplasia of the esophagus or stomach with an indication for oncological surgery with curative intent.
  • INCLUSION CRITERIA: patients with surgical indication and curative intention due to esophagogastric neoplasm who do not meet exclusion criteria and recruited by hospitals nationwide that decide to participate in the study.
  • EXCLUSION CRITERIA
  • Patients under 18 or over 85 years
  • Patients with chronic infections
  • Patients with synchronous tumors in other locations
  • Patients with autoimmune disease
  • Patients who die in the operating room
  • Patients who do not sign the informed consent to participate in the study
  • Patients in clinical stage IVB
  • Surgical resection R2 (there are macroscopic remains of the tumor in the surgical field after performing the resection of the surgical piece)
  • Combined intraoperative resection of other organs
  • Surgeries without anastomosis
  • MONITORING: The patient will be monitored during the first 90 postoperative days. 5.-DURATION OF THE STUDY The time for the inclusion of patients in the study will be 1 year in each center from the incorporation of the first of their patients.
Read the detailed description

The methodological properties of the study are described below:

  1. - Type of design Prospective and multicenter study that aims to develop, with the help of artificial intelligence methods, a tool and predictive model that allows identifying cases with a high risk of anastomotic leak and/or major complications through the analysis of different clinical and analytical variables collected during the postoperative period. of patients undergoing esophagectomy or gastrectomy.
  2. - Study population Patients diagnosed with neoplasia of the esophagus or stomach with an indication for oncological surgery with curative intent in any of the centers participating in the study.
  3. - Inclusion and exclusion criteria Patients with a surgical indication and curative intent due to esophagogastric neoplasia who do not meet exclusion criteria and recruited by hospitals nationwide that decide to participate in the study will be included. The study exclusion criteria are:
  • Patients under 18 or over 85 years
  • Patients with chronic infections
  • Patients with synchronous tumors in other locations
  • Patients with autoimmune disease
  • Patients who die in the operating room
  • Patients who do not sign the informed consent to participate in the study
  • Patients in clinical stage IVB
  • Surgical resection R2 (there are macroscopic remains of the tumor in the surgical field after performing the resection of the surgical piece)
  • Combined intraoperative resection of other organs
  • Surgeries without anastomosis In addition, the following situations are considered criteria for abandonment or withdrawal of the patient from the study:
  • Revocation of the informed consent expressed by the patient at any time during the study.
  • Patient loss during study follow-up
  • Incorrect data collection according to the indications provided
  1. - Sample size The purpose of the study is to recruit as many patients as possible from all national centers who wish to participate. For an alpha error of 5% (95% confidence) with a precision of 3% and estimating a number of patients with major complications (including AF) around 30%, the calculation of the sample size yields a total of 847 patients. However, the final sample size may be smaller depending on the proportion of complications detected and the statistical and artificial intelligence models to create the predictive model will be adapted to the event rate provided by the recruited sample.
  2. - Recruitment All patients who meet the inclusion and exclusion criteria will be offered preoperative participation in this study. Once the information has been understood (Annex 1) and the written informed consent (Annex 2) has been signed, each patient will be assigned a code that will be used to anonymously manage any of their information obtained during the study. Thus, the confidentiality of the data belonging to all the patients included in the study will be guaranteed at all times from the moment of recruitment.
  3. - Intervention The patient will undergo the indicated surgical intervention depending on whether it is an esophageal or gastric neoplasm, with curative intent with or without prior neoadjuvant treatment. Surgical intervention and postoperative care will be carried out in each of the centers of the national territory that commit to participate according to their usual clinical practice. Thus, the perioperative management and care protocol will be that of each center without the need to apply exceptional measures (beyond the control of the clinical and analytical variables of this study) or a homogeneous protocol in all the participating centers. The analysis and control of the preoperative clinical variables must be carried out the day before or the same day of the surgical intervention prior to it.
  4. - Follow up The patient will be monitored during the first 90 postoperative days, compiling all the specific variables of this study and the possible complications and mortality that occurred in this period. During the immediate postoperative period, apart from the care applied routinely in each center, patients should be evaluated daily and the clinical and laboratory variables specified later should be collected on days 1, 2, 3, 4 and 6 postoperatively. In the same way, in this postoperative course, the possible complications that appeared during the hospital stay will be compiled. Subsequently, if the patient is discharged from the hospital, a follow-up will be carried out in the outpatient consultations at 30 and 90 days to evaluate the possible complications that appear in this period and other variables studied will be completed.
  5. - Database and study variables

The variables collected throughout the study protocol will be collected on the following dates of assistance, care, control and follow-up of the patient.

Being tested
audit of complications, prospective data collection
Keywords
esophagectomy, gastrectomy, leak
Medical subject headings
Esophageal Neoplasms, Stomach Neoplasms, Anastomotic Leak

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • audit of complications, prospective data collectionOther

    Prospective colecction of data will be performed to create a predictive model of leak and major complication

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. anastomotic leak

    a categorical variable divided into the following categories, according to the consensus definitions of the Consensus Group on Complications of Esophagectomy (ECCG) (27), which in this study will be applicable both to fistulas occurred after esophagectomy and after gastrectomy:

    • NO: If this complication did not occur.
    • I: Defect that does not require specific treatment or that can be treated medically or with diet modification
    • II: Defect that requires some intervention, but not surgical, such as: drainage by interventional radiology, prosthesis placement, opening of the wound at the bedside, compression or wound healing.
    • III: Defect requiring surgical intervention

    Measured: 90 postoperative days

Secondary outcomes (5)
  1. major complication

    Clavien Dindo > III

    Measured: 90 postoperative days

  2. chylothorax

    Categorical variable divided into the categories according to the consensus definitions of the Consensus Group on Complications of Esophagectomy (ECCG)

    Measured: 90 postoperative days

  3. plasty necrosis

    Categorical variable divided into the categories according to the consensus definitions of the Consensus Group on Complications of Esophagectomy (ECCG)

    Measured: 90 postoperative days

  4. recurrent nerve plasy

    Categorical variable divided into the categories according to the consensus definitions of the Esophagectomy Complications Consensus Group (ECCG)

    Measured: 90 postoperative days

  5. infection

    Dichotomous variable: YES/NO.

    Measured: 90 postoperative days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 May 2022
  2. Study start1 May 2022
  3. Primary completion1 Dec 2023 (estimated)
  4. Study completion31 Dec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
800 participants (estimated)
Target duration
90 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT05390684
Sponsor's protocol ID
AEC-PROFUGO
Acronym
PROFUGO
Status last verified
May 2022
First submitted
16 May 2022
Last updated
25 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Esophagus Cancer and Gastric Cancer, run by Hospital Universitario La Fe at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

anastomotic leak (time frame: 90 postoperative days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in